(Q36134796)

12 August 2017

Assesssment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer (English)

1 reference

12 August 2017

Gazet JC

1

1 reference

12 August 2017

Coombes RC

2

1 reference

12 August 2017

Ford HT

3

1 reference

12 August 2017

Griffin M

4

1 reference

12 August 2017

Corbishley C

5

1 reference

12 August 2017

Makinde V

6

1 reference

12 August 2017

Lowndes S

7

1 reference

12 August 2017

Quilliam J

8

1 reference

12 August 2017

Sutcliffe R

9

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 March 1996

1 reference

British Journal of Cancer

12 August 2017

1 reference

12 August 2017

73

1 reference

12 August 2017

6

1 reference

12 August 2017

758-762

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.1996.132

12 August 2017

0 references

cites work

Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074387

Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074387

Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074387

Use of luteinising hormone-releasing hormone agonist (leuprorelin) in advanced post-menopausal breast cancer: clinical and endocrine effects

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074387

Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074387

Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074387

A dose-comparative endocrine-clinical study of leuprorelin in premenopausal breast cancer patients

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074387

A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074387

A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074387

Primary systemic therapy for operable breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074387

Randomised trial of chemotherapy versus endocrine therapy in patients presenting with locally advanced breast cancer (a pilot study)

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074387

4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074387

Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074387

The management of locally advanced breast cancer

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074387

Assessment of biochemical tests to screen for metastases in patients with breast cancer

2 July 2018

1 reference

12 December 2020

Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer

1 reference

12 December 2020

1 reference

12 December 2020

Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer

1 reference

12 December 2020

Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer

1 reference

12 December 2020

Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a Cancer and Leukemia Group B study

1 reference

12 December 2020

Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione

1 reference

12 December 2020

Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma

1 reference

12 December 2020

Primary medical (neo-adjuvant) chemotherapy for operable breast cancer

1 reference

12 December 2020

Multimodal treatment for locally advanced breast cancer. Result of chemotherapy-radiotherapy versus chemotherapy-surgery

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1996.132

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

8611376

1 reference